183 patents currently held
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
49
Ending by 2030
Jan 2027
Next term end
93
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2031 · High confidence
Also notable
Ends Jul 2030 · High confidence
Also notable
Ends Mar 2034 · High confidence
Also notable
Ends Aug 2027 · High confidence
Also notable
Ends Nov 2031 · High confidence
Also notable
Ends Mar 2030 · High confidence
Also notable
Ends Jul 2031 · High confidence
Also notable
Ends Feb 2037 · High confidence
Oplophorus-Derived Luciferases, Novel Coelenterazine Substrates, and Methods of Use
US 8,669,103
Cited by 91 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Synthetic Oplophorus Luciferases with Enhanced Light Output
US 8,557,970
The most cited patent in this portfolio, cited by 118 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2030.
Activation of Bioluminescence by Structural Complementation
US 9,797,890
Cited by 28 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Luminogenic and Fluorogenic Compounds and Methods to Detect Molecules or Conditions
US 7,951,550
Cited by 62 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Imidazo[1,2-a]pyrazine Derivatives
US 8,809,529
Cited by 79 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression
US 8,420,367
Cited by 34 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Mutant Protease Biosensors with Enhanced Detection Characteristics
US 8,735,559
Cited by 26 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES AND PREPARATION METHOD THEREOF
US 9,924,073
The largest patent family in this portfolio, 7 related applications, renewed at every maintenance window due so far. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 23 to 30, 2026 · next Nov 23
- 6 fees due Dec 2 to 16, 2026 · next Dec 2
- 3 fees due Jan 4 to 30, 2027 · next Jan 4
- 2 fees due Feb 4 to 28, 2027 · next Feb 4
- 4 fees due Mar 3 to 26, 2027 · next Mar 3
- 4 fees due Apr 1 to 30, 2027 · next Apr 1
- 3 fees due Jun 8 to 24, 2027 · next Jun 8
- 1 fee due Jul 2, 2027The maintenance fee for Quinone-Containing Conjugates (US 11,857,638) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 6 fees due Aug 2 to 27, 2027 · next Aug 2
- 6 fees due Sep 1 to 26, 2027 · next Sep 1
- 3 fees due Oct 14 to 28, 2027 · next Oct 14
- 2 fees due Nov 12 to 17, 2027 · next Nov 12
Recent changes
- 2 of the patents on this record were granted since Aug 22, 2026
- 2 terms have ended since Aug 22, 2026
- Oct 13 US 7,700,310 Method for Detecting Transferase Enzymatic Activity · term ended
- Sep 18 US 10,077,433 Permuted and Nonpermuted Luciferase Biosensors · lapsed on the fee record
What they patent
The largest of its 93 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,781,472 | Systems and Methods for Determining Cyclic Nucleotide Concentration and Related Pathway Activation In force · High confidence | In force | High confidence | |
| US 8,658,360 | Nucleic Acid Purification with a Binding Matrix In force · High confidence | In force | High confidence | |
| US 7,891,549 | Biological Sample Processing Apparatus That Selects the Personality Type of the Apparatus In force · High confidence | In force | High confidence | |
| US 7,951,550 | Luminogenic and Fluorogenic Compounds and Methods to Detect Molecules or Conditions In force · High confidence | In force | High confidence | |
| US 8,748,148 | Polynucleotides Encoding Mutant Hydrolase Proteins with Enhanced Kinetics and Functional Expression In force · High confidence | In force | High confidence | |
| US 9,593,316 | Polynucleotides Encoding Mutant Hydrolase Proteins with Enhanced Kinetics and Functional Expression In force · High confidence | In force | High confidence | |
| US 9,873,866 | Mutant Dehalogenase Proteins In force · High confidence | In force | High confidence | |
| US 10,246,690 | Mutant Hydrolase Proteins with Enhanced Kinetics and Functional Expression In force · High confidence | In force | High confidence | |
| US D695,295 | Adapter for Hand-Held Electronic Devices In force · High confidence | In force | High confidence | |
| US 9,012,164 | Bioluminescent Assays Utilising Secreted Luciferases In force · High confidence | In force | High confidence |
Also on record, not counted in the 183: 17 patents in force now held by others · 114 patents ended · 42 applications pending · 66 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.